Poor
Poorly Aligned
Patient Risk:
Moderate
Summary
The response accurately identifies Vascepa's use for severe hypertriglyceridemia and generally reflects its cardiovascular-risk reduction indication, but it omits important labeled conditions and makes numerous pricing and assistance-program claims not addressed by the supplied prescribing information.
Category Scores
Accurate Statements
Vascepa is used to treat severe hypertriglyceridemia.
Supported as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia, defined in the label as triglycerides of at least 500 mg/dL.
Unsupported Statements
Vascepa costs approximately $250–$300 per month.
The supplied prescribing information contains no pricing information.
Amarin Corporation offers a Vascepa discount program that provides eligible patients with reduced out-of-pocket costs.
The supplied prescribing information does not describe discount programs or out-of-pocket costs.
The Vascepa discount program is not available to all patients.
Program availability and eligibility are not addressed in the supplied prescribing information.
Eligibility for the Vascepa discount program requires a valid prescription for Vascepa.
Discount-program eligibility requirements are not addressed in the supplied prescribing information.
Eligibility for the Vascepa discount program includes being uninsured or underinsured.
Insurance-status requirements are not addressed in the supplied prescribing information.
Eligibility for the Vascepa discount program includes having an annual household income of $100,000 or less.
Income eligibility criteria are not addressed in the supplied prescribing information.
Patients eligible for government-funded programs such as Medicare or Medicaid are not eligible for the Vascepa discount program.
Medicare, Medicaid, and other program restrictions are not addressed in the supplied prescribing information.
Patients can apply for the Vascepa discount program through the Amarin Corporation website or by contacting their healthcare provider.
Application procedures and contact information are not addressed in the supplied prescribing information.
The application for the Vascepa discount program typically requires proof of income, insurance status, and other relevant documentation.
Application documentation requirements are not addressed in the supplied prescribing information.
Patient assistance programs may provide eligible patients with free or reduced-cost Vascepa.
Patient assistance programs and reduced-cost medication are not addressed in the supplied prescribing information.
Amarin Corporation offers a manufacturer coupon that can reduce the cost of Vascepa.
Manufacturer coupons and cost reductions are not addressed in the supplied prescribing information.
Discount cards may reduce the cost of Vascepa.
Discount cards and medication pricing are not addressed in the supplied prescribing information.
Contradictions
Important Omissions
The cardiovascular-risk reduction indication requires use as an adjunct to maximally tolerated statin therapy in adults with elevated triglycerides and established cardiovascular disease, or diabetes mellitus with at least two additional cardiovascular risk factors.
Importance:
High
The severe-hypertriglyceridemia indication applies to adults with triglyceride levels of at least 500 mg/dL and specifies use as an adjunct to diet.
Importance:
High
The label states that the effect of Vascepa on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The unsupported financial and assistance-program claims could mislead patients about medication cost or access. The indication statements also omit material population, triglyceride-level, diet, and statin-therapy conditions, although no direct contradiction of the supplied label is made.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Poorly Aligned
Primary Issue
Most financial, discount, coupon, and patient-assistance claims are not supported by the supplied prescribing information, and the labeled indication requirements are incompletely stated.
Suggested Improvement
Restrict label-based claims to the approved indications and include the required statin therapy, diet, triglyceride threshold, and eligible patient populations. Clearly identify pricing and assistance-program information as outside the supplied prescribing information rather than presenting it as label-supported.